About this Journal Submit a Manuscript Table of Contents
Mediators of Inflammation
Volume 2013 (2013), Article ID 759103, 10 pages
http://dx.doi.org/10.1155/2013/759103
Review Article

Pivotal Roles of Monocytes/Macrophages in Stroke

Information Center, National Institute of Health and Nutrition, 1-23-1 Toyama, Shinjuku-ku, Tokyo 162-8636, Japan

Received 12 October 2012; Accepted 2 January 2013

Academic Editor: Kuen-Jer Tsai

Copyright © 2013 Tsuyoshi Chiba and Keizo Umegaki. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. W. Rosamond, K. Flegal, G. Friday et al., “Heart disease and stroke statistics—2007 Update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee,” Circulation, vol. 115, no. 5, pp. e69–e171, 2007. View at Publisher · View at Google Scholar · View at Scopus
  2. L. B. Goldstein, C. D. Bushnell, R. J. Adams, et al., “Guidelines for the primary prevention of stroke: a Guideline for Healthcare Professionals from the American Heart Association/American Stroke Association,” Stroke, vol. 42, no. 2, pp. 517–584, 2011. View at Publisher · View at Google Scholar
  3. G. J. Blake and P. M. Ridker, “Inflammatory bio-markers and cardiovascular risk prediction,” Journal of Internal Medicine, vol. 252, no. 4, pp. 283–294, 2002. View at Publisher · View at Google Scholar · View at Scopus
  4. K. Fassbender, T. Bertsch, O. Mielke, F. Mühlhauser;, and M. Hennerici, “Adhesion molecules in cerebrovascular diseases: evidence for an inflammatory endothelial activation in cerebral large- and small-vessel disease,” Stroke, vol. 30, no. 8, pp. 1647–1650, 1999. View at Scopus
  5. C. Sánchez-Moreno, J. F. Dashe, T. Scott, D. Thaler, M. F. Folstein, and A. Martin, “Decreased levels of plasma vitamin C and increased concentrations of inflammatory and oxidative stress markers after stroke,” Stroke, vol. 35, no. 1, pp. 163–168, 2004. View at Publisher · View at Google Scholar · View at Scopus
  6. A. Arakelyan, J. Petrkova, Z. Hermanova, A. Boyajyan, J. Lukl, and M. Petrek, “Serum levels of the MCP-1 chemokine in patients with ischemic stroke and myocardial infarction,” Mediators of Inflammation, vol. 2005, no. 3, pp. 175–179, 2005. View at Publisher · View at Google Scholar · View at Scopus
  7. R. L. Prentice, T. P. Szatrowski, H. Kato, and M. W. Mason, “Leukocyte counts and cerebrovascular disease,” Journal of Chronic Diseases, vol. 35, no. 9, pp. 703–714, 1982. View at Scopus
  8. M. Fava, “Leukocytes and the risk of ischemic diseases,” JAMA, vol. 258, no. 7, pp. 907–908, 1987. View at Scopus
  9. R. F. Gillum, D. D. Ingram, and D. M. Makuc, “White blood cell count and stroke incidence and death: the NHANES I epidemiologic follow-up study,” American Journal of Epidemiology, vol. 139, no. 9, pp. 894–902, 1994. View at Scopus
  10. A. J. Grau, A. W. Boddy, D. A. Dukovic et al., “Leukocyte count as an independent predictor of recurrent ischemic events,” Stroke, vol. 35, no. 5, pp. 1147–1152, 2004. View at Publisher · View at Google Scholar · View at Scopus
  11. A. D. Blann, W. Tse, S. J. R. Maxwell, and M. A. Waite, “Increased levels of the soluble adhesion molecule E-selectin in essential hypertension,” Journal of Hypertension, vol. 12, no. 8, pp. 925–928, 1994. View at Scopus
  12. C. A. Desouza, D. R. Dengel, R. F. Macko, K. Cox, and D. R. Seals, “Elevated levels of circulating cell adhesion molecules in uncomplicated essential hypertension,” American Journal of Hypertension, vol. 10, no. 12, pp. 1335–1341, 1997. View at Publisher · View at Google Scholar · View at Scopus
  13. A. Madej, B. Okopień, J. Kowalski, M. Haberka, and Z. S. Herman, “Plasma concentrations of adhesion molecules and chemokines in patients with essential hypertension,” Pharmacological Reports, vol. 57, no. 6, pp. 878–881, 2005. View at Scopus
  14. A. C. Newby, “Metalloproteinase expression in monocytes and macrophages and its relationship to atherosclerotic plaque instability,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 12, pp. 2108–2114, 2008. View at Publisher · View at Google Scholar · View at Scopus
  15. R. Ross, “Atherosclerosis—an inflammatory disease,” The New England Journal of Medicine, vol. 340, no. 2, pp. 115–126, 1999. View at Publisher · View at Google Scholar · View at Scopus
  16. C. M. Dollery and P. Libby, “Atherosclerosis and proteinase activation,” Cardiovascular Research, vol. 69, no. 3, pp. 625–635, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. A. Bar-Or, R. K. Nuttall, M. Duddy et al., “Analyses of all matrix metalloproteinase members in leukocytes emphasize monocytes as major inflammatory mediators in multiple sclerosis,” Brain, vol. 126, no. 12, pp. 2738–2749, 2003. View at Publisher · View at Google Scholar · View at Scopus
  18. A. C. Newby, “Dual role of matrix metalloproteinases (matrixins) in intimal thickening and atherosclerotic plaque rupture,” Physiological Reviews, vol. 85, no. 1, pp. 1–31, 2005. View at Publisher · View at Google Scholar · View at Scopus
  19. J. L. Johnson, G. B. Sala-Newby, Y. Ismail, C. M. Aguilera, and A. C. Newby, “Low tissue inhibitor of metalloproteinases 3 and high matrix metalloproteinase 14 levels defines a subpopulation of highly invasive foam-cell macrophages,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 28, no. 9, pp. 1647–1653, 2008. View at Publisher · View at Google Scholar · View at Scopus
  20. A. C. Newby, “Do metalloproteinases destabilize vulnerable atherosclerotic plaques?” Current Opinion in Lipidology, vol. 17, no. 5, pp. 556–561, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. M. Schilling, M. Besselmann, C. Leonhard, M. Mueller, E. B. Ringelstein, and R. Kiefer, “Microglial activation precedes and predominates over macrophage infiltration in transient focal cerebral ischemia: a study in green fluorescent protein transgenic bone marrow chimeric mice,” Experimental Neurology, vol. 183, no. 1, pp. 25–33, 2003. View at Publisher · View at Google Scholar · View at Scopus
  22. R. Tanaka, M. Komine-Kobayashi, H. Mochizuki et al., “Migration of enhanced green fluorescent protein expressing bone marrow-derived microglia/macrophage into the mouse brain following permanent focal ischemia,” Neuroscience, vol. 117, no. 3, pp. 531–539, 2003. View at Publisher · View at Google Scholar · View at Scopus
  23. K. Nakajima and S. Kohsaka, “Microglia: activation and their significance in the central nervous system,” Journal of Biochemistry, vol. 130, no. 2, pp. 169–175, 2001. View at Scopus
  24. R. B. Banati, J. Gehrmann, P. Schubert, and G. W. Kreutzberg, “Cytotoxicity of microglia,” GLIA, vol. 7, no. 1, pp. 111–118, 1993. View at Scopus
  25. F. C. Barone, B. Arvin, R. F. White et al., “Tumor necrosis factor-α: a mediator of focal ischemic brain injury,” Stroke, vol. 28, no. 6, pp. 1233–1244, 1997. View at Scopus
  26. N. Rothwell, S. Allan, and S. Toulmond, “The role of interleukin 1 in acute neurodegeneration and stroke: pathophysiological and therapeutic implications,” The Journal of Clinical Investigation, vol. 100, no. 11, pp. 2648–2652, 1997. View at Scopus
  27. M. Schilling, M. Besselmann, M. Müller, J. K. Strecker, E. B. Ringelstein, and R. Kiefer, “Predominant phagocytic activity of resident microglia over hematogenous macrophages following transient focal cerebral ischemia: an investigation using green fluorescent protein transgenic bone marrow chimeric mice,” Experimental Neurology, vol. 196, no. 2, pp. 290–297, 2005. View at Publisher · View at Google Scholar · View at Scopus
  28. M. Schilling, J. K. Strecker, W. R. Schäbitz, E. B. Ringelstein, and R. Kiefer, “Effects of monocyte chemoattractant protein 1 on blood-borne cell recruitment after transient focal cerebral ischemia in mice,” Neuroscience, vol. 161, no. 3, pp. 806–812, 2009. View at Publisher · View at Google Scholar · View at Scopus
  29. K. G. Petry, C. Boiziau, V. Dousset, and B. Brochet, “Magnetic resonance imaging of human brain macrophage infiltration,” Neurotherapeutics, vol. 4, no. 3, pp. 434–442, 2007. View at Publisher · View at Google Scholar · View at Scopus
  30. Y. Yamori, “Predictive and preventive pathology of cardiovascular diseases,” Acta Pathologica Japonica, vol. 39, no. 11, pp. 683–705, 1989. View at Scopus
  31. T. Chiba and O. Ezaki, “Dietary restriction suppresses inflammation and delays the onset of stroke in stroke-prone spontaneously hypertensive rats,” Biochemical and Biophysical Research Communications, vol. 399, no. 1, pp. 98–103, 2010. View at Publisher · View at Google Scholar · View at Scopus
  32. M. Gelderblom, F. Leypoldt, K. Steinbach et al., “Temporal and spatial dynamics of cerebral immune cell accumulation in stroke,” Stroke, vol. 40, no. 5, pp. 1849–1857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. J. Huang, U. M. Upadhyay, and R. J. Tamargo, “Inflammation in stroke and focal cerebral ischemia,” Surgical Neurology, vol. 66, no. 3, pp. 232–245, 2006. View at Publisher · View at Google Scholar · View at Scopus
  34. T. V. Arumugam, D. N. Granger, and M. P. Mattson, “Stroke and T-cells,” NeuroMolecular Medicine, vol. 7, no. 3, pp. 229–242, 2005. View at Publisher · View at Google Scholar · View at Scopus
  35. B. Dahlöf, “Prevention of stroke in patients with hypertension,” American Journal of Cardiology, vol. 100, no. 3, supplement, pp. S17–S24, 2007. View at Publisher · View at Google Scholar
  36. A. J. Palmer, C. J. Bulpitt, A. E. Fletcher et al., “Relation between blood pressure and stroke mortality,” Hypertension, vol. 20, no. 5, pp. 601–605, 1992. View at Scopus
  37. P. J. Marvar, H. Lob, A. Vinh, F. Zarreen, and D. G. Harrison, “The central nervous system and inflammation in hypertension,” Current Opinion in Pharmacology, vol. 11, no. 2, pp. 156–161, 2011. View at Publisher · View at Google Scholar · View at Scopus
  38. C. Iadecola and R. L. Davisson, “Hypertension and cerebrovascular dysfunction,” Cell Metabolism, vol. 7, no. 6, pp. 476–484, 2008. View at Publisher · View at Google Scholar · View at Scopus
  39. M. Pate, V. Damarla, D. S. Chi, S. Negi, and G. Krishnaswamy, “Endothelial cell biology. Role in the inflammatory response,” Advances in Clinical Chemistry, vol. 52, pp. 109–130, 2010. View at Publisher · View at Google Scholar · View at Scopus
  40. H. Wang, J. Nawata, N. Kakudo et al., “The upregulation of ICAM-1 and P-selectin requires high blood pressure but not circulating renin-angiotensin system in vivo,” Journal of Hypertension, vol. 22, no. 7, pp. 1323–1332, 2004. View at Publisher · View at Google Scholar · View at Scopus
  41. C. A. Lemarié, B. Esposito, A. Tedgui, and S. Lehoux, “Pressure-induced vascular activation of nuclear factor-κB: role in cell survival,” Circulation Research, vol. 93, no. 3, pp. 207–212, 2003. View at Publisher · View at Google Scholar · View at Scopus
  42. I. Palomo, P. Marín, M. Alarcón et al., “Patients with essential hypertension present higher levels of sE-selectin and sVCAM-1 than normotensive volunteers,” Clinical and Experimental Hypertension, vol. 25, no. 8, pp. 517–523, 2003. View at Publisher · View at Google Scholar · View at Scopus
  43. Y. Liu, T. Liu, R. M. McCarron et al., “Evidence for activation of endothelium and monocytes in hypertensive rats,” American Journal of Physiology, vol. 270, no. 6, pp. H2125–H2131, 1996. View at Scopus
  44. G. W. Schmid-Schonbein, D. Seiffge, F. A. DeLano, K. Shen, and B. W. Zweifach, “Leukocyte counts and activation in spontaneously hypertensive and normotensive rats,” Hypertension, vol. 17, no. 3, pp. 323–330, 1991. View at Scopus
  45. M. Clozel, H. Kuhn, F. Hefti, and H. R. Baumgartner, “Endothelial dysfunction and subendothelial monocyte macrophages in hypertension: effect of angiotensin converting enzyme inhibition,” Hypertension, vol. 18, no. 2, pp. 132–141, 1991. View at Scopus
  46. Y. Dörffel, C. Lätsch, B. Stuhlmüller et al., “Preactivated peripheral blood monocytes in patients with essential hypertension,” Hypertension, vol. 34, no. 1, pp. 113–117, 1999. View at Scopus
  47. E. M. A. Mervaala, D. N. Müller, J. K. Park et al., “Monocyte infiltration and adhesion molecules in a rat model of high human renin hypertension,” Hypertension, vol. 33, no. 1, part 2, pp. 389–395, 1999. View at Scopus
  48. J. Theuer, R. Dechend, D. Muller et al., “Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats,” BMC Cardiovascular Disorders, vol. 2, article 3, 2002. View at Publisher · View at Google Scholar · View at Scopus
  49. T. Imakiire, Y. Kikuchi, M. Yamada et al., “Effects of renin-angiotensin system blockade on macrophage infiltration in patients with hypertensive nephrosclerosis,” Hypertension Research, vol. 30, no. 7, pp. 635–642, 2007. View at Publisher · View at Google Scholar · View at Scopus
  50. M. A. Saleh, E. I. Boesen, J. S. Pollock, V. J. Savin, and D. M. Pollock, “Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat,” Hypertension, vol. 56, no. 5, pp. 942–949, 2010. View at Publisher · View at Google Scholar · View at Scopus
  51. U. N. Das, “Is angiotensin-II an endogenous pro-inflammatory molecule?” Medical Science Monitor, vol. 11, no. 5, pp. RA155–RA162, 2005. View at Scopus
  52. H. R. Vianna, C. M. Soares, M. S. Tavares, M. M. Teixeira, and A. C. Silva, “Inflammation in chronic kidney disease: the role of cytokines,” Jornal Brasileiro de Nefrologia, vol. 33, no. 3, pp. 351–364, 2011.
  53. L. Sironi, E. Nobili, A. Gianella, P. Gelosa, and E. Tremoli, “Anti-inflammatory properties of drugs acting on the renin-angiotensin system,” Drugs of Today, vol. 41, no. 9, pp. 609–622, 2005. View at Publisher · View at Google Scholar · View at Scopus
  54. K. Okamoto, Y. Yamori, and A. Nagaoka, “Establishment of the stroke prone spontaneously hypertensive rat (SHR),” Circulation Research, vol. 34, no. 1, pp. 143–153, 1974. View at Scopus
  55. L. Sironi, U. Guerrini, E. Tremoli et al., “Analysis of pathological events at the onset of brain damage in stroke-prone rats: a proteomics and magnetic resonance imaging approach,” Journal of Neuroscience Research, vol. 78, no. 1, pp. 115–122, 2004. View at Publisher · View at Google Scholar · View at Scopus
  56. M. Volpe, G. Iaccarino, C. Vecchione et al., “Association and cosegregation of stroke with impaired endothelium- dependent vasorelaxation in stroke prone, spontaneously hypertensive rats,” The Journal of Clinical Investigation, vol. 98, no. 2, pp. 256–261, 1996. View at Scopus
  57. L. Sironi, E. Gianazza, P. Gelosa et al., “Rosuvastatin, but not simvastatin, provides end-organ protection in stroke-prone rats by antiinflammatory effects,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 25, no. 3, pp. 598–603, 2005. View at Publisher · View at Google Scholar · View at Scopus
  58. R. Wilcox, M. G. Bousser, D. J. Betteridge et al., “Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04),” Stroke, vol. 38, no. 3, pp. 865–873, 2007. View at Publisher · View at Google Scholar · View at Scopus
  59. T. Nakamura, E. Yamamoto, K. Kataoka et al., “Pioglitazone exerts protective effects against stroke in stroke-prone spontaneously hypertensive rats, independently of blood pressure,” Stroke, vol. 38, no. 11, pp. 3016–3022, 2007. View at Publisher · View at Google Scholar · View at Scopus
  60. T. Ishizuka, A. Niwa, M. Tabuchi, K. Ooshima, and H. Higashino, “Acetylsalicylic acid provides cerebrovascular protection from oxidant damage in salt-loaded stroke-prone rats,” Life Sciences, vol. 82, no. 13-14, pp. 806–815, 2008. View at Publisher · View at Google Scholar · View at Scopus
  61. M. Schroeter, S. Jander, O. W. Witte, and G. Stoll, “Local immune responses in the rat cerebral cortex after middle cerebral artery occlusion,” Journal of Neuroimmunology, vol. 55, no. 2, pp. 195–203, 1994. View at Publisher · View at Google Scholar · View at Scopus
  62. D. L. Small and A. M. Buchan, “Animal models,” British Medical Bulletin, vol. 56, no. 2, pp. 307–317, 2000. View at Scopus
  63. Y. Chen, A. Ito, K. Takai, and N. Saito, “Blocking pterygopalatine arterial blood flow decreases infarct volume variability in a mouse model of intraluminal suture middle cerebral artery occlusion,” Journal of Neuroscience Methods, vol. 174, no. 1, pp. 18–24, 2008. View at Publisher · View at Google Scholar · View at Scopus
  64. D. Tsuchiya, S. Hong, T. Kayama, S. S. Panter, and P. R. Weinstein, “Effect of suture size and carotid clip application upon blood flow and infarct volume after permanent and temporary middle cerebral artery occlusion in mice,” Brain Research, vol. 970, no. 1-2, pp. 131–139, 2003. View at Publisher · View at Google Scholar · View at Scopus
  65. N. Beckmann, “High resolution magnetic resonance angiography non-invasively reveals mouse strain differences in the cerebrovascular anatomy in vivo,” Magnetic Resonance in Medicine, vol. 44, no. 2, pp. 252–258, 2000. View at Publisher · View at Google Scholar
  66. F. C. Barone, D. J. Knudsen, A. H. Nelson, G. Z. Feuerstein, and R. N. Willette, “Mouse strain differences in susceptibility to cerebral ischemia are related to cerebral vascular anatomy,” Journal of Cerebral Blood Flow and Metabolism, vol. 13, no. 4, pp. 683–692, 1993. View at Scopus
  67. W. C. Dornas and M. E. Silva, “Animal models for the study of arterial hypertension,” Journal of Biosciences, vol. 36, no. 4, pp. 731–737, 2011. View at Publisher · View at Google Scholar
  68. N. Nishijo, F. Sugiyama, K. Kimoto et al., “Salt-sensitive aortic aneurysm and rupture in hypertensive transgenic mice that overproduce angiotensin II,” Laboratory Investigation, vol. 78, no. 9, pp. 1059–1066, 1998. View at Scopus
  69. S. Iida, G. L. Baumbach, J. L. Lavoie, F. M. Faraci, C. D. Sigmund, and D. D. Heistad, “Spontaneous stroke in a genetic model of hypertension in mice,” Stroke, vol. 36, no. 6, pp. 1253–1258, 2005. View at Publisher · View at Google Scholar · View at Scopus
  70. S. S. Shaftel, T. J. Carlson, J. A. Olschowka, S. Kyrkanides, S. B. Matousek, and M. K. O'Banion, “Chronic interleukin-1β expression in mouse brain leads to leukocyte infiltration and neutrophil-independent blood-brain barrier permeability without overt neurodegeneration,” Journal of Neuroscience, vol. 27, no. 35, pp. 9301–9309, 2007. View at Publisher · View at Google Scholar · View at Scopus
  71. H. Boutin, R. A. LeFeuvre, R. Horai, M. Asano, Y. Iwakura, and N. J. Rothwell, “Role of IL-1α and IL-1β in ischemic brain damage,” Journal of Neuroscience, vol. 21, no. 15, pp. 5528–5534, 2001. View at Scopus
  72. V. Banwell, E. S. Sena, and M. R. Macleod, “Systematic review and stratified meta-analysis of the efficacy of interleukin-1 receptor antagonist in animal models of stroke,” Journal of Stroke and Cerebrovascular Diseases, vol. 18, no. 4, pp. 269–276, 2009. View at Publisher · View at Google Scholar · View at Scopus
  73. H. C. A. Emsley, C. J. Smith, R. F. Georgiou et al., “A randomised phase II study of interleukin-1 receptor antagonist in acute stroke patients,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 76, no. 10, pp. 1366–1372, 2005. View at Publisher · View at Google Scholar · View at Scopus
  74. A. A. Rezaii, S. M. Hoseinipanah, M. Hajilooi, A. R. Rafiei, N. Shikh, and M. Haidari, “Interleukin-1 receptor antagonist gene polymorphism and susceptibility to ischemic stroke,” Immunological Investigations, vol. 38, no. 3-4, pp. 220–230, 2009. View at Publisher · View at Google Scholar · View at Scopus
  75. S. Olsson, L. Holmegaard, K. Jood et al., “Genetic variation within the interleukin-1 gene cluster and ischemic stroke,” Stroke, vol. 43, no. 9, pp. 2278–2282, 2012. View at Publisher · View at Google Scholar
  76. W. Whiteley, C. Jackson, S. Lewis et al., “Inflammatory markers and poor outcome after stroke: a prospective cohort study and systematic review of interleukin-6,” PLoS Medicine, vol. 6, no. 9, Article ID e1000145, 2009. View at Publisher · View at Google Scholar · View at Scopus
  77. W. M. Clark, L. G. Rinker, N. S. Lessov et al., “Lack of interleukin-6 expression is not protective against focal central nervous system ischemia,” Stroke, vol. 31, no. 7, pp. 1715–1720, 2000. View at Scopus
  78. J. Scheller, A. Chalaris, D. Schmidt-Arras, and S. Rose-John, “The pro- and anti-inflammatory properties of the cytokine interleukin-6,” Biochimica et Biophysica Acta, vol. 1813, no. 5, pp. 878–888, 2011. View at Publisher · View at Google Scholar · View at Scopus
  79. J. Zaremba and J. Losy, “Early TNF-α levels correlate with ischaemic stroke severity,” Acta Neurologica Scandinavica, vol. 104, no. 5, pp. 288–295, 2001. View at Publisher · View at Google Scholar · View at Scopus
  80. E. Shohami, I. Ginis, and J. M. Hallenbeck, “Dual role of tumor necrosis factor alpha in brain injury,” Cytokine and Growth Factor Reviews, vol. 10, no. 2, pp. 119–130, 1999. View at Publisher · View at Google Scholar · View at Scopus
  81. J. M. Hallenbeck, “The many faces of tumor necrosis factor in stroke,” Nature Medicine, vol. 8, no. 12, pp. 1363–1368, 2002. View at Publisher · View at Google Scholar · View at Scopus
  82. H. Nawashiro, D. Martin, and J. M. Hallenbeck, “Inhibition of tumor necrosis factor and amelioration of brain infarction in mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 17, no. 2, pp. 229–232, 1997. View at Scopus
  83. H. Nawashiro, K. Tasaki, C. A. Ruetzler, and J. M. Hallenbeck, “TNF-α pretreatment induces protective effects against focal cerebral ischemia in mice,” Journal of Cerebral Blood Flow and Metabolism, vol. 17, no. 5, pp. 483–490, 1997. View at Scopus
  84. C. Banfi, L. Sironi, G. De Simoni et al., “Pentoxifylline prevents spontaneous brain ischemia in stroke-prone rats,” Journal of Pharmacology and Experimental Therapeutics, vol. 310, no. 3, pp. 890–895, 2004. View at Publisher · View at Google Scholar · View at Scopus
  85. A. Vakili, S. Mojarrad, M. M. Akhavan, and A. Rashidy-Pour, “Pentoxifylline attenuates TNF-α protein levels and brain edema following temporary focal cerebral ischemia in rats,” Brain Research, vol. 1377, pp. 119–125, 2011. View at Publisher · View at Google Scholar · View at Scopus
  86. J. Zaremba, J. Ilkowski, and J. Losy, “Serial measurements of levels of the chemokines CCL2, CCL3 and CCL5 in serum of patients with acute ischaemic stroke,” Folia Neuropathologica, vol. 44, no. 4, pp. 282–289, 2006. View at Scopus
  87. P. M. Hughes, P. R. Allegrini, M. Rudin, V. H. Perry, A. K. Mir, and C. Wiessner, “Monocyte chemoattractant protein-1 deficiency is protective in a murine stroke model,” Journal of Cerebral Blood Flow and Metabolism, vol. 22, no. 3, pp. 308–317, 2002. View at Scopus
  88. P. Mathieu, P. Poirier, P. Pibarot, I. Lemieux, and J. P. Després, “Visceral obesity the link among inflammation, hypertension, and cardiovascular disease,” Hypertension, vol. 53, no. 4, pp. 577–584, 2009. View at Publisher · View at Google Scholar · View at Scopus
  89. J. E. Hall, A. A. Da Silva, J. M. Do Carmo et al., “Obesity-induced hypertension: role of sympathetic nervous system, leptin, and melanocortins,” The Journal of Biological Chemistry, vol. 285, no. 23, pp. 17271–17276, 2010. View at Publisher · View at Google Scholar · View at Scopus
  90. F. Yiannikouris, M. Gupte, K. Putnam, and L. Cassis, “Adipokines and blood pressure control,” Current Opinion in Nephrology and Hypertension, vol. 19, no. 2, pp. 195–200, 2010. View at Publisher · View at Google Scholar · View at Scopus
  91. S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, “Obesity is associated with macrophage accumulation in adipose tissue,” The Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003. View at Publisher · View at Google Scholar · View at Scopus
  92. A. Bouloumié, C. A. Curat, C. Sengenès, K. Lolmède, A. Miranville, and R. Busse, “Role of macrophage tissue infiltration in metabolic diseases,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 8, no. 4, pp. 347–354, 2005.
  93. B. J. Kim, S.-H. Lee, W.-S. Ryu, C. K. Kim, and B.-W. Yoon, “Adipocytokines and ischemic stroke: differential associations between stroke subtypes,” Journal of the Neurological Sciences, vol. 312, no. 1-2, pp. 117–122, 2012. View at Publisher · View at Google Scholar
  94. S. Gerdes, S. Osadtschy, M. Rostami-Yazdi, N. Buhles, M. Weichenthal, and U. Mrowietz, “Leptin, adiponectin, visfatin and retinol-binding protein-4—mediators of comorbidities in patients with psoriasis?” Experimental Dermatology, vol. 21, no. 1, pp. 43–47, 2012. View at Publisher · View at Google Scholar
  95. C. Prugger, G. Luc, B. Haas et al., “Adipocytokines and the risk of ischemic stroke: the PRIME Study,” Annals of Neurology, vol. 71, no. 4, pp. 478–486, 2012. View at Publisher · View at Google Scholar
  96. S. Söderberg, D. Colquhoun, A. Keech et al., “Leptin, but not adiponectin, is a predictor of recurrent cardiovascular events in men: results from the LIPID study,” International Journal of Obesity, vol. 33, no. 1, pp. 123–130, 2009. View at Publisher · View at Google Scholar · View at Scopus
  97. S. I. Yamagishi, D. Edelstein, X. L. Du, Y. Kaneda, M. Guzmán, and M. Brownlee, “Leptin induces mitochondrial superoxide production and monocyte chemoattractant protein-1 expression in aortic endothelial cells by increasing fatty acid oxidation via protein kinase A,” The Journal of Biological Chemistry, vol. 276, no. 27, pp. 25096–25100, 2001. View at Publisher · View at Google Scholar · View at Scopus
  98. S. Loffreda, S. Q. Yang, H. Z. Lin et al., “Leptin regulates proinflammatory immune responses,” The FASEB Journal, vol. 12, no. 1, pp. 57–65, 1998. View at Scopus
  99. E. J. Folco, V. Z. Rocha, M. López-Ilasaca, and P. Libby, “Adiponectin inhibits pro-inflammatory signaling in human macrophages independent of interleukin-10,” The Journal of Biological Chemistry, vol. 284, no. 38, pp. 25569–25575, 2009. View at Publisher · View at Google Scholar · View at Scopus
  100. K. Ohashi, J. L. Parker, N. Ouchi et al., “Adiponectin promotes macrophage polarization toward an anti-inflammatory phenotype,” The Journal of Biological Chemistry, vol. 285, no. 9, pp. 6153–6160, 2010. View at Publisher · View at Google Scholar · View at Scopus
  101. M. Kumada, S. Kihara, N. Ouchi et al., “Adiponectin specifically increased tissue inhibitor of metalloproteinase-1 through interleukin-10 expression in human macrophages,” Circulation, vol. 109, no. 17, pp. 2046–2049, 2004. View at Publisher · View at Google Scholar · View at Scopus
  102. J. Thundyil, D. Pavlovski, C. G. Sobey, and T. V. Arumugam, “Adiponectin receptor signalling in the brain,” British Journal of Pharmacology, vol. 165, no. 2, pp. 313–327, 2012.
  103. J. M. Friedman, “Leptin, leptin receptors and the control of body weight,” European Journal of Medical Research, vol. 2, no. 1, pp. 7–13, 1997. View at Scopus
  104. P. M. Ridker, E. Danielson, F. A. H. Fonseca et al., “Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein,” The New England Journal of Medicine, vol. 359, no. 21, pp. 2195–2207, 2008. View at Publisher · View at Google Scholar · View at Scopus
  105. P. Amarenco, J. Labreuche, P. Lavallée, and P. J. Touboul, “Statins in stroke prevention and carotid atherosclerosis: systematic review and up-to-date meta-analysis,” Stroke, vol. 35, no. 12, pp. 2902–2909, 2004. View at Publisher · View at Google Scholar · View at Scopus
  106. J. K. Liao, “Beyond lipid lowering: the role of statins in vascular protection,” International Journal of Cardiology, vol. 86, no. 1, pp. 5–18, 2002. View at Publisher · View at Google Scholar · View at Scopus
  107. C. J. Vaughan, “Prevention of stroke and dementia with statins: effects beyond lipid lowering,” American Journal of Cardiology, vol. 91, no. 4, supplement, pp. 23–29, 2003. View at Publisher · View at Google Scholar · View at Scopus
  108. M. D. I. Vergouwen, R. J. De Haan, M. Vermeulen, and Y. B. W. E. M. Roos, “Statin treatment and the occurrence of hemorrhagic stroke in patients with a history of cerebrovascular disease,” Stroke, vol. 39, no. 2, pp. 497–502, 2008. View at Publisher · View at Google Scholar · View at Scopus
  109. I. B. Puddey, “Low serum cholesterol and the risk of cerebral haemorrhage,” Atherosclerosis, vol. 119, no. 1, pp. 1–6, 1996. View at Publisher · View at Google Scholar · View at Scopus
  110. A. T. White and A. N. Murphy, “Administration of thiazolidinediones for neuroprotection in ischemic stroke: a pre-clinical systematic review,” Journal of Neurochemistry, vol. 115, no. 4, pp. 845–853, 2010. View at Publisher · View at Google Scholar · View at Scopus
  111. X. Zhao, J. Grotta, N. Gonzales, and J. Aronowski, “Hematoma resolution as a therapeutic target: the role of microglia/macrophages,” Stroke, vol. 40, no. 3, pp. S92–S94, 2009. View at Publisher · View at Google Scholar · View at Scopus
  112. J. A. Dormandy, B. Charbonnel, D. J. Eckland et al., “Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial,” The Lancet, vol. 366, no. 9493, pp. 1279–1289, 2005. View at Publisher · View at Google Scholar · View at Scopus
  113. D. J. Graham, R. Ouellet-Hellstrom, T. E. Macurdy et al., “Risk of acute myocardial infarction, stroke, heart failure, and death in elderly medicare patients treated with rosiglitazone or pioglitazone,” JAMA, vol. 304, no. 4, pp. 411–418, 2010. View at Publisher · View at Google Scholar · View at Scopus
  114. J. E. Buring, “A perspective on the women's healthy study: aspirin prevents stroke but not MI in Women; Vitamin E has no effect on CV disease or cancer,” Cleveland Clinic Journal of Medicine, vol. 73, no. 9, pp. 863–870, 2006. View at Publisher · View at Google Scholar · View at Scopus
  115. M. Tymianski, “Aspirin as a promising agent for decreasing incidence of cerebral aneurysm rupture,” Stroke, vol. 42, no. 11, pp. 3003–3004, 2011. View at Publisher · View at Google Scholar
  116. P. Gelosa, R. Ballerio, C. Banfi et al., “Terutroban, a thromboxane/prostaglandin endoperoxide receptor antagonist, increases survival in stroke-prone rats by preventing systemic inflammation and endothelial dysfunction: comparison with aspirin and rosuvastatin,” Journal of Pharmacology and Experimental Therapeutics, vol. 334, no. 1, pp. 199–205, 2010. View at Publisher · View at Google Scholar · View at Scopus
  117. M. G. Bousser, P. Amarenco, A. Chamorro et al., “Rationale and design of a randomized, double-blind, parallel-group study of terutroban 30 mg/day versus aspirin 100 mg/day in stroke patients: the prevention of cerebrovascular and cardiovascular events of ischemic origin with terutroban in patients with a history of ischemic stroke or transient ischemic attack (PERFORM) study,” Cerebrovascular Diseases, vol. 27, no. 5, pp. 509–518, 2009. View at Publisher · View at Google Scholar · View at Scopus
  118. M. G. Bousser, P. Amarenco, A. Chamorro et al., “Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial,” The Lancet, vol. 377, no. 9782, pp. 2013–2022, 2011. View at Publisher · View at Google Scholar · View at Scopus
  119. Y. Kitamura, D. Yanagisawa, M. Inden et al., “Recovery of focal brain ischemia-induced behavioral dysfunction by intracerebroventricular injection of microglia,” Journal of Pharmacological Sciences, vol. 97, no. 2, pp. 289–293, 2005. View at Publisher · View at Google Scholar · View at Scopus
  120. Y. Kitamura, K. Takata, M. Inden et al., “Intracerebroventricular injection of microglia protects against focal brain ischemia,” Journal of Pharmacological Sciences, vol. 94, no. 2, pp. 203–206, 2004. View at Publisher · View at Google Scholar · View at Scopus
  121. P. E. Batchelor, G. T. Liberatore, J. Y. F. Wong et al., “Activated macrophages and microglia induce dopaminergic sprouting in the injured striatum and express brain-derived neurotrophic factor and glial cell line-derived neurotrophic factor,” Journal of Neuroscience, vol. 19, no. 5, pp. 1708–1716, 1999. View at Scopus
  122. K. Nakajima and S. Kohsaka, “Microglia: neuroprotective and neurotrophic cells in the central nervous system,” Current Drug Targets, vol. 4, no. 1, pp. 65–84, 2004. View at Publisher · View at Google Scholar · View at Scopus
  123. S. L. O'Donnell, T. J. Frederick, J. K. Krady, S. J. Vannucci, and T. L. Wood, “IGF-I and microglia/macrophage proliferation in the ischemic mouse brain,” GLIA, vol. 39, no. 1, pp. 85–97, 2002. View at Publisher · View at Google Scholar · View at Scopus
  124. M. LaThe Lancette-Hébert, G. Gowing, A. Simard, C. W. Yuan, and J. Kriz, “Selective ablation of proliferating microglial cells exacerbates ischemic injury in the brain,” Journal of Neuroscience, vol. 27, no. 10, pp. 2596–2605, 2007. View at Publisher · View at Google Scholar · View at Scopus
  125. U. K. Hanisch and H. Kettenmann, “Microglia: active sensor and versatile effector cells in the normal and pathologic brain,” Nature Neuroscience, vol. 10, no. 11, pp. 1387–1394, 2007. View at Publisher · View at Google Scholar · View at Scopus
  126. H. Ohtaki, J. H. Ylostalo, J. E. Foraker et al., “Stem/progenitor cells from bone marrow decrease neuronal death in global ischemia by modulation of inflammatory/immune responses,” Proceedings of the National Academy of Sciences of the United States of America, vol. 105, no. 38, pp. 14638–14643, 2008. View at Publisher · View at Google Scholar · View at Scopus
  127. C. L. Gibson, T. C. Coughlan, and S. P. Murphy, “Glial nitric oxide and ischemia,” GLIA, vol. 50, no. 4, pp. 417–426, 2005. View at Publisher · View at Google Scholar · View at Scopus
  128. H. Hattori, S. Suzuki, Y. Okazaki, N. Suzuki, and M. Kuwana, “Intracranial transplantation of monocyte-derived multipotential cells enhances recovery after ischemic stroke in rats,” Journal of Neuroscience Research, vol. 90, no. 2, pp. 479–488, 2012. View at Publisher · View at Google Scholar